[HTML][HTML] Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach
…, S Eppler, P Kuebler, LA Damico-Beyer… - … & visual science, 2013 - iovs.arvojournals.org
Methods.: A population approach of nonlinear mixed-effect pharmacokinetic modeling based
on concentration-time data from 2993 serum samples from 674 AMD patients enrolled in 5 …
on concentration-time data from 2993 serum samples from 674 AMD patients enrolled in 5 …
A guide to rational dosing of monoclonal antibodies
…, Y Xin, D Jin, Y Zheng, LA Damico-Beyer… - Clinical …, 2012 - Springer
Background and Objective Dosing of therapeutic monoclonal antibodies (mAbs) is often
based on body size, with the perception that body size-based dosing would reduce inter-subject …
based on body size, with the perception that body size-based dosing would reduce inter-subject …
Complement inhibition in cynomolgus monkeys by anti–factor D antigen-binding fragment for the treatment of an advanced form of dry age-related macular …
…, PC Haughney, A Morimoto, LA Damico-Beyer… - … of Pharmacology and …, 2014 - ASPET
Anti–factor D (AFD; FCFD4514S, lampalizumab) is a humanized IgG Fab fragment directed
against factor D (fD), a rate-limiting serine protease in the alternative complement pathway (…
against factor D (fD), a rate-limiting serine protease in the alternative complement pathway (…
Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration–effect data to support clinical development
…, E Mai, J Young, A Peterson, LA Damico-Beyer - Clinical Cancer …, 2013 - AACR
Purpose: We characterized the pharmacokinetics of onartuzumab (MetMAb) in animals and
determined a concentration–effect relationship in tumor-bearing mice to enable estimation of …
determined a concentration–effect relationship in tumor-bearing mice to enable estimation of …
A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy
…, KM Loyet, A Morimoto, J Jin, LA Damico-Beyer… - … of Pharmacology and …, 2015 - ASPET
Lampalizumab is an antigen-binding fragment of a humanized monoclonal antibody against
complement factor D (CFD), a rate-limiting enzyme in the activation and amplification of the …
complement factor D (CFD), a rate-limiting enzyme in the activation and amplification of the …
Development and preclinical characterization of a humanized antibody targeting CXCL12
…, J Yao, R Takkar, WP Lee, LA Damico-Beyer… - Clinical Cancer …, 2013 - AACR
Purpose: Our goal was to develop a potent humanized antibody against mouse/human
CXCL12. This report summarized its in vitro and in vivo activities. Experimental Design: Cell …
CXCL12. This report summarized its in vitro and in vivo activities. Experimental Design: Cell …
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
…, G Schaefer, MX Sliwkowski, LA Damico-Beyer - Cancer chemotherapy …, 2012 - Springer
Purpose MEHD7945A is a novel dual-action monoclonal antibody in which each of the two
antigen-binding fragments is capable of binding to EGFR and HER3 with high affinity. It is …
antigen-binding fragments is capable of binding to EGFR and HER3 with high affinity. It is …
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced …
Y Xin, D Jin, S Eppler, LA Damico‐Beyer… - The Journal of …, 2013 - Wiley Online Library
Onartuzumab is a unique, humanized, monovalent (one‐armed) monoclonal antibody (mAb)
against the MET receptor. The intravenous (IV) pharmacokinetics (PK) of onartuzumab …
against the MET receptor. The intravenous (IV) pharmacokinetics (PK) of onartuzumab …
Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t (4; 14) …
…, H Li, J Tien, J Qing, LA Damico-Beyer - Cancer chemotherapy …, 2012 - Springer
Purpose MFGR1877A is a human IgG1 monoclonal antibody that binds to fibroblast growth
factor receptor 3 (FGFR3) and is being investigated as a potential therapy for relapsed/…
factor receptor 3 (FGFR3) and is being investigated as a potential therapy for relapsed/…
Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans
Y Xin, S Bai, LA Damico-Beyer, D Jin, WC Liang… - Pharmaceutical …, 2012 - Springer
Purpose To compare the pharmacokinetics (PK) of MNRP1685A, a human monoclonal
antibody (mAb) against neuropilin-1 (NRP1), in mice, rats, monkeys, and cancer patients from a …
antibody (mAb) against neuropilin-1 (NRP1), in mice, rats, monkeys, and cancer patients from a …